Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020


Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the in vitro diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
November 2020
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

The Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020 report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.


This report provides details of the latest In Vitro Diagnostics agreements announced in the life sciences since 2014.


The report takes the reader through a comprehensive review In Vitro Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering In Vitro Diagnostics partnering deals.


The report presents financial deal term values for In Vitro Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.


The middle section of the report explores the leading dealmakers in the In Vitro Diagnostics partnering field; both the leading deal values and most active In Vitro Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.


One of the key highlights of the report is that over 550 online deal records of actual In Vitro Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.


In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.


The initial chapters of this report provide an orientation of In Vitro Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in In Vitro Diagnostics dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.


Chapter 3 provides a review of the leading In Vitro Diagnostics deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.


Chapter 4 provides a comprehensive listing of the top 25 most active companies in In Vitro Diagnostics dealmaking with a brief summary followed by a comprehensive listing of In Vitro Diagnostics deals announded by that company, as well as contract documents, where available.


Chapter 5 provides a comprehensive and detailed review of In Vitro Diagnostics partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.


Chapter 6 provides a comprehensive and detailed review of In Vitro Diagnostics partnering deals signed and announced since Jan 2014. The chapter is organized by specific In Vitro Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.


A comprehensive series of appendices is provided organized by In Vitro Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.


The report also includes numerous tables and figures that illustrate the trends and activities in In Vitro Diagnostics partnering and dealmaking since 2014.


In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of In Vitro Diagnostics technologies and products.


Key benefits


Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020 provides the reader with the following key benefits:


  • In-depth understanding of In Vitro Diagnostics deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of In Vitro Diagnostics agreements with numerous real life case studies
  • Detailed access to actual In Vitro Diagnostics contracts entered into by leading biopharma companies
  • Identify most active In Vitro Diagnostics dealmakers since 2014
  • Insight into terms included in a In Vitro Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies


Report scope


Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020 is intended to provide the reader with an in-depth understanding and access to In Vitro Diagnostics trends and structure of deals entered into by leading companies worldwide.


In Vitro Diagnostics Partnering Terms and Agreements includes:


  • Trends in In Vitro Diagnostics dealmaking in the biopharma industry since 2014
  • Analysis of In Vitro Diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life In Vitro Diagnostics deals
  • Access to In Vitro Diagnostics contract documents
  • Leading In Vitro Diagnostics deals by value since 2014
  • Most active In Vitro Diagnostics dealmakers since 2014


In Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020, the available deals are listed by:


  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type


Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


The Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020 report provides comprehensive access to available deals and contract documents for over 550 In Vitro Diagnostics deals.


Analyzing actual contract agreements allows assessment of the following:


  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020 report provides the reader with the following key benefits:


  • In-depth understanding of In Vitro Diagnostics deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of In Vitro Diagnostics agreements with numerous real life case studies
  • Detailed access to actual In Vitro Diagnostics contracts entered into by leading biopharma companies
  • Identify most active In Vitro Diagnostics dealmakers since 2014
  • Insight into terms included in a In Vitro Diagnostics partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in In Vitro Diagnostics dealmaking


2.1. Introduction

2.2. In Vitro Diagnostics partnering over the years

2.3. Most active In Vitro Diagnostics dealmakers

2.4. In Vitro Diagnostics partnering by deal type

2.5. In Vitro Diagnostics partnering by therapy area

2.6. Deal terms for In Vitro Diagnostics partnering

2.6.1 In Vitro Diagnostics partnering headline values

2.6.2 In Vitro Diagnostics deal upfront payments

2.6.3 In Vitro Diagnostics deal milestone payments

2.6.4 In Vitro Diagnostics royalty rates


Chapter 3 – Leading In Vitro Diagnostics deals


3.1. Introduction

3.2. Top In Vitro Diagnostics deals by value


Chapter 4 – Most active In Vitro Diagnostics dealmakers


4.1. Introduction

4.2. Most active In Vitro Diagnostics dealmakers

4.3. Most active In Vitro Diagnostics partnering company profiles


Chapter 5 – In Vitro Diagnostics contracts dealmaking directory


5.1. Introduction

5.2. In Vitro Diagnostics contracts dealmaking directory


Chapter 6 – In Vitro Diagnostics dealmaking by technology type


Chapter 7 – Partnering resource center


7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking




Appendix 1 – In Vitro Diagnostics deals by company A-Z


Appendix 2 – In Vitro Diagnostics deals by stage of development




Phase I

Phase II

Phase III





Appendix 3 – In Vitro Diagnostics deals by deal type


Asset purchase


Bigpharma outlicensing


Collaborative R&D







Equity purchase



Joint venture





Material transfer





Spin out



Technology transfer




Appendix 4 – In Vitro Diagnostics deals by therapy area


Appendix 5 –Deal type definitions


About Wildwood Ventures


Current Partnering

Current Agreements

Recent report titles from Current Partnering


Table of figures


Figure 1: In Vitro Diagnostics partnering since 2014

Figure 2: Active In Vitro Diagnostics dealmaking activity since 2014

Figure 3: In Vitro Diagnostics partnering by deal type since 2014

Figure 4: In Vitro Diagnostics partnering by disease type since 2014

Figure 5: In Vitro Diagnostics deals with a headline value

Figure 6: In Vitro Diagnostics deals with an upfront value

Figure 7: In Vitro Diagnostics deals with a milestone value

Figure 8: In Vitro Diagnostics deals with a royalty rate value

Figure 9: Top In Vitro Diagnostics deals by value since 2014

Figure 10: Most active In Vitro Diagnostics dealmakers since 2014

Figure 11: Online partnering resources

Figure 12: Forthcoming partnering events

Pricing options


  • $3,495: single-user
  • $5,245: multi-user
  • $10,495: single site license
  • $17,495: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2cureX, 3M, 3PrimeDx, 10X Genomics, 23andMe, 36 Strategies General Trading, A*STAR Institute of Microelectronics (IME), AB Analitica, Abbott Laboratories, Abbott Rapid Diagnostics, Abcam, Abionic, Access BIO, Accurate Diagnostic Laboratories, Accuscience, AceCGT Life Science, Acon Labs, Actelion, Adaptive Phage Therapeutics, Adeptrix, Adial Pharmaceuticals, ADT Altona Diagnostic Technologies, Advanced Biological Laboratories, Advanced Cooling Therapy, Advanced Dermatology and Cosmetic Surgery Group, Aegea Biotechnologies, Aerocrine, Aethlon Medical, Agena Bioscience, Agendia, Agilent Technologies, AID Genomics, AI Metrics, Air Force General Hospital, AirStrip Technologies, AIT Laboratories, Akers Biosciences, AKSA Medical, Alab, Alere, Algenex, ALK-Abello, AllerGenis, Alliance Pharma, ALR Technologies, Alveo Technologies, Al Zahrawi Medical Supplies, Amarantus BioSciences, A Menarini Diagnostics, America's Choice Provider Network, American Medical Depot, American Pathology Partners, AmpTec, AMRA, Amydis Diagnostics, Anixa Biosciences, Anpac Bio-Medical Science, ANP Technologies, Apollo Med Innovations, Appistry, Apple, Applied DNA Sciences, Appriss Health, Aptagen, ArcherDX, Arches Research, Ares Genetics, Ariosa Diagnostics, Arkray, Arkray USA, Armed Forces Medical Research Institute, Arno Therapeutics (inactive since 2017), Arquer Diagnostics, Arterial Health International, ASPiRA Labs, Association for Frontotemporal Degeneration, AstraZeneca, AstraZeneca HealthCare Foundation, Astute Medical, Asuragen, ATGen Global, Atomo Diagnostics, Austrian Institute of Technology, Avacta, Avalon GloboCare, Avellino Labs, AVL Sofia, Avrobio, Axonlab, AyoxxA Biosystems, Aytu BioScience, Babson Diagnostics, Baker IDI Heart and Diabetes Institute, Banc De Sang I Teixits, Banyan Biomarkers, BASF, Battelle, Baxter International, Bayer, Bayer Healthcare, Baylor College of Medicine, Beckman Coulter, Becton Dickinson, Beijing Clear Biotech, Beijing Leadman Biochemistry, Beijing Yuan Jian Health Management, Bestmed, Best Supplies, Better Living Now, Beurer, Bill and Melinda Gates Foundation, Binx Health, Bio-Manguinhos, Bio-Rad Laboratories, Bio-Techne, bioAffinity Technologies, BioCanna Healthcare, Biocartis, Biocept, BioFire Diagnostics, BIOgenetiX, BioGen Medical, Biohit, BioIQ, BioLab Sciences, BioMarker Strategies, Biomedical Advanced Research and Development Authority, BIOMEDX Group, BioMed X Innovation Center, bioMerieux, Biomnis, Bioportugal Quimica Farmaceutica, BioReference Laboratories, BioSyntagma, Biotage, BioTecon Diagnostics, BioTelemetry, BioVendor, Bioventix, Biozym Scientific, Bird Foundation, Blood Centers of America, Bluejay Diagnostics, BMV Medica, Bode Technology, Boehringer Ingelheim Vetmedica, Bonnie J. Addario Lung Cancer Foundation, Boston Scientific, Boston University, Boston University School of Medicine, Breakthrough Diagnostics, Bristol-Myers Squibb, Broad Institute, Burnet Institute, C2N Diagnostics, Cambridge Bioscience, Cambridge Cognition, Cancer Genetics, Canon U.S. Life Sciences, Capnia, Caputron Medical, CARB-X, CardiNor, CardioDx, CardioLogic, Cardiorentis, CareDx, Care GB Plus, Carl Zeiss Meditec, Case Western Reserve University, CBD Vida, Celgene, Cellgen Diagnostics, Cell Marque, CellSafe, Centaur, Centene, Center for Connected Health, Center for Human Genetics and Laboratory Medicine, Centers for Disease Control and Prevention, Cepheid, Cernostics, Chembio Diagnostics, Children's Hospital Boston, Children’s Hospital Oakland Research Institute (CHORI), Chun Fo Pharmaceutical, CIRCA Scientific, Clarity Pharmaceuticals, Clinical Genomics, CliniSciences, CNC Biotech, Co-Diagnostics, Collective Medical, Columbia University, CombiMatrix, Common Sense, Commonwealth Laboratories, Companion Medical, Compumedics, Confirm BioSciences, Copan Diagnostics, Corgenix Medical, Corvida Medical, Corvium, CPT Medical, Crown Dental + Medical, Cue Health, Curative, Curetis, Cynvenio, Cytiva, Cytox, Dako, Daktari Diagnostics, Dana-Farber Cancer Institute, DarioHealth, DaRui Biotech, DASA, DaVita HealthCare Partners, Daxor, DCN Diagnostics, Debiopharm, Decision Diagnostics, Defense Threat Reduction Agency, Dehaier Medical Systems, Department of Defense, Department of Health and Human Services, Department of Veterans Affairs, Dermpath Diagnostics, DermTech, DexCom, DiaCarta, DiagnoCure, Diasend, DiaSorin, Diassess, Diasys Diagnostics Systems, Diatherix, Diaxonhit, DigiPath Solutions, DKSH, DNAnexus, Doping Control Center, Duke Medical, Duke University, DxTerity, Dynasty Castle Investments, E25Bio, EarlySense, Easton Pharmaceuticals, Echosens, Ecole Polytechnique Federale de Lausanne, Eddingpharm, Eiken Chemical, EKF Diagnostics, EKF Diagnostics (Germany), Eldan, Ellume, Empatica, Enable Biosciences, Ender Diagnostics, Endocanna Health, Endotronix, Enterome Bioscience, Enzo Clinical Labs, Epigenomics, Erasmus University Medical Center, Eureka Eurostars, Eurobio, Eurofins Genomics, Eurofins LifeCodexx, European Commission, Event Cardio Group, EverlyWell, Evogen, Exact Imaging, Exagen Diagnostics, Exalenz Bioscience, Exosome Diagnostics, Exosome Sciences, ExoStat Medical, Expedeon, Eyesense, Ez Sleep Technologies, FABPulous, Facebook, Felkasta JSC, Ferring Pharmaceuticals, Fio, First Check Diagnostics, Fisher Healthcare, FitBit, Fleming Fund, Flemish agency for Innovation by Science and Technology, Fluxergy, Fluxion Biosciences, Fortelinea Software Systems, Fosun Pharmaceutical, Foundation for Innovative New Diagnostics, Fraunhofer Institute for Microelectronic Circuits and Systems, Fresenius Kabi Pharmaceuticals, Fukuda Denshi, Fulgent Genetics, Galapagos, Galectin Therapeutics, Gedeon Richter, GE Healthcare, Gen-Probe, GenCell Biosystems, Genelabs Technologies, GeneNews, Genentech, Genetic Analysis, Genetic Technologies, Genoma, Genomic Health, Genomics England, Genomic Testing Cooperative, GensKey Medical Technology, Gentag, GenTegra, George Mason University, George Washington University, GHR Foundation, GIMDx, Ginkgo BioWorks, Global Discovery Biosciences, Global Dx, Global Good Fund, Global WholeHealth Partners, Glooko, GlySens, Glytec, GNA Biosolutions, Gnomegen, GNYHA Services, Good Start Genetics, Google, Government of Canada, Gravity Diagnostics, Greenfield Global, Greiner Bio-One, Group K Diagnostics, Guangzhou Pharmaceutical Group, Guardant Health, Guided Therapeutics, GuoMinXinHe Investment Fund, Gyros Protein Technologies, Halozyme Therapeutics, Hamilton Robotics, Hartford HealthCare, Harvard Bioscience, Healgen Scientific, Healthcare 21, Health Network Laboratories, Healthsense, HeartGenetics, Helix, HelixBind, Hememics Biotechnologies, Henry M. Jackson Foundation, Herzog Surgical, HiberGene Diagnostics, Hob Diagnostics, Hologic, Hong Kong Polytechnic University, Hoowaki, Horizon 2020, Horizon Discovery, Horizon Therapeutics, Hoth Therapeutics, HTG Molecular Diagnostics, Huakang Biomedical, Human Longevity, Hvidovre Hospital, I-MED Pharma, iBIO Institute’s PROPEL Center, IDEAS DWC, Idera Pharmaceuticals, Illumina, IMI, ImmunArray, Immuno Diagnostic, Imperial College London, IncellDx, Infectolab Americas, Inivata, Innova Biosciences, Innovation Zed, Innovative Diagnostic Laboratory, Innovus Pharmaceuticals, Inserm, Insight Genetics, Institut Curie, Institute for Global Food Security, Institute of Molecular Biology of Paraná (IBMP), Institut Gustave Roussy, Insulet, Integrated DNA Technologies, Integrity Applications, Intrinsic LifeSciences, Invitae, InVivoScribe, Ionis Pharmaceuticals, IPMD, IQ-AI, iRhythm Technology, ISIS Innovation, Istituto Diagnostico Varelli, Itamar Medical, Jan Medical, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Johns Hopkins University, Johnson & Johnson Innovation, Johnson & Johnson Vision, John Wayne Cancer Institute, Joint Venture Partner Group, Jubilant Radiopharma, Kantaro Biosciences, Karius, KingMed Diagnostics, Kings College London, KMG International, Know Labs, Kore, L1 Systems, Lab21, Laboratorios LETI, Laboratory Corporation of America, Laboratory Supply Company (LABSCO), LabPro, LabStyle Innovations, Lark Technologies, LDR Holding, Lee's Pharmaceutical, Leica Biosystems, Leidos Holdings, Lexent Bio, LifeCaring Technologies, LifeCell, LifeCodexx, LifeLabs Medical Laboratory Services, LifeScan, Life Technologies Corporation, LifeWatch Services, Lineagen, LivaNova, Liverpool School of Tropical Medicine, Living Heart Foundation, Livongo Health, Longhorn Vaccines and Diagnostics, Lucid Diagnostics, Luminex, Lumiphore, Lunaphore, Lutheran Medical Center, Lyra Health, MagBioSense, Magentine, MagnaCare, Magnet Sales and Manufacturing, Makerere University, Marken, Masimo, Massachusetts General Hospital, Massachusetts Institute of Technology, Massachusetts Life Sciences Center, Mass General Brigham, Masterlab, Matrix Medical Network, Mayo Clinic, Mayo Medical Laboratories, MBio Diagnostics, McKesson, MD Anderson Cancer Center, MDL Asia, MDxHealth, MediBeacon, Medibio, Medical College of Wisconsin, Medical Marijuana, Medical Research Foundation, Medicinal Genomics, Medidata Solutions, Medigus, Medimass, MediReva, Medisur, MedMira, Medtronic, Medusa19, Medx, Mellitus, Memorial Sloan Kettering Cancer Center, Merck and Co, Meridian Bioscience, Meridian Health Services Network, Mesa Biotech, Mesa Laboratories, Methapharm, Metro Health, MGC Diagnostics, MicrobeDx, Microdrop, MicroGEM, Micropoint Bioscience, MicroPort Scientific, Microprofit Biotech, MikroLink, Ministry of Health (Brazil), Ministry of Health (Saudi Arabia), Miraca Life Sciences, Mitani Sangyo, Mitobridge, Mitsui, Mobidiag, MolecularMD, Mologic, Monsanto, Motic, Mount Sinai Health System, MyLabBox, Mylan Laboratories, N-of-One, Naka International, Nanobeak, Nanommune, NanoMosaic, NanoPin Technologies, NanoSpeed Diagnostics, NanoString Technologies, Nanowear, Narayana Nethralaya Foundation, NASA, NASH Network, Natera, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Center for Foreign Animal and Zoonotic Disease Defense, National Heart, Lung and Blood Institute, National Institute for Environmental Health Sciences, National Institute for Innovation in Manufacturing Biopharmaceuticals, National Institute for Public Health and the Environment, National Institute of Allergy and Infectious Diseases, National Institute of Child Health and Human Development, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, National Institute of Standards and Technology, National Institute on Aging, National Institutes of Health, National Research Council Canada, National Science Foundation, Nationwide Laboratory Services, Naval Medical Logistics Command, Navidea Biopharmaceuticals, Navy Medical Research Centre, Nemaura Medical, Neogen, NEO New Oncology, Neoteric Technology, Nephron Pharmaceuticals, NeuroMetrix, Neurosoft, Neurotrack, Neurovirtual, New Jersey Urology, Newmars Group, New York City Health and Hospital, NextCODE Health, NG Biotech, Nicox, Nicoya, Nima, Nimble Therapeutics, Nipro Corporation, Nipro Diagnostics, NLC Pharma, Nonacus, Nordic Biolabs, North Georgia Healthcare, NovaBay Pharmaceuticals, Novartis, Novation, Noviosense, Novoheart, Nuclea Biotechnologies, Nucleix, numares, NuProbe, Ohio Department of Development, Ohio State Innovation Foundation, Ohio State University, Oklahoma Medical Research Foundation, OmeCare, Omixon, OmniPathology, Omron, Oncgnostics, Oncimmune, One BioMed, One Drop, One Medical, Ontera, OPKO Health, Optimed, Opto-Systems, OraSure Technologies, OrigiMed, Orot+, OrSense, Ortho-Clinical Diagnostics, Osteolabs, Oswaldo Cruz Foundation (Fiocruz), Otsuka, Owlstone Medical, Oxford Immunotec, Oxgene, Pansend, Paradigm, PathogenDx, Pathway Diagnostics, Paul G Allen Family Foundation, PAVmed, Pax Neuroscience, Perinatal Quality Foundation, Peripal, PerkinElmer, Personal Genome Diagnostics, Pfizer, Pharma Tech Solutions, Phosphorus Genomics, Pierre Fabre, Pippa Mann, Plexus, PositiveID, PreCheck, PredictImmune, Premier Inc, Preora Diagnostics, Prescient Medical, Prevencio, Preventice, Primary Bio, ProciseDx, Progentec Diagnostics, Pro Med Diagnostics, Promega, ProNova, ProPath, Prostate Cancer Foundation (PCF), Providence Saint John's Health Center, Public Health England, Q-linea AB, Qiagen, Quanterix, QuantumDx, Quaphaco, Quest Diagnostics, Quidel, QuiO Technologies, Quotient Biodiagnostics, Quotient Bioscience, Racer Technology, Radboud University Nijmegen Medical Centre, Raiing Medical, RayBiotech, Regis Technologies, Relay Medical, RenalytixAI, Renegade Bio, Respiratory Motion, Reszon Diagnostics, Revon Systems, Ridge Diagnostics, Robert H. Lurie Comprehensive Cancer Center, Roche, Roche Diagnostics, Roka Bioscience, Romer Labs, Royal Philips Electronics, Rubicon Genomics, Rutgers University, Saladax Biomedical, Salk Institute, Samsung Electronics, Sanvita, Savonix, Scanwell Health, Schott, SciBase, Scienion, SD Biosensor, Seattle Childrens Research Institute, Sebia, Secant Medical, Securiport, Seegene, Sekisui Diagnostics, Semiotik, Senseonics, Sensible Medical Innovations, Sensocure, Sentio, Sequenom, Sequenta, Seracare Life Sciences, Seventh Sense Biosystems, Shandong Yingsheng Biotechnology, Shanghai Industrial µTechnology Research Institute (SITRI), Shanghai Nanodigmnio Biotechnology, Sherlock Biosciences, Shuwen Biotech, Siemens Healthcare, Siemens Healthcare Diagnostics, Siemens Healthineers, Singapore Eye Research Institute (SERI), Singulex, Sintact Medical Systems, SkylineDX, Skyline Urology, Smart Meter, Sona Nanotech, Sony DADC, Sopachem, Sorrento Therapeutics, SpeeDx, Spinomix, Spirosure, SQI Diagnostics, Stago, Stanford University, Stellar Technologies, St Georges University of London, Stony Brook University, Stop TB Partnership, STRATEC Biomedical Systems AG, Sugentech, Sumocor, Sunnybrook Health Sciences Centre, Susan G. Komen for the Cure, SYGNIS Pharma, Symcel, SynapDx, Synthetic Biologics, SystemOne, T2 Biosystems, Takara Bio USA, Talis Biomedical, Tangen Biosciences, Tauriga Sciences, TB Alliance, TBG Management, Tecan, Telenatal, TeraRecon, Texas AgriLife Research, The Native Antigen Company, Theradiag, Theranostica, Thermo Fisher Scientific, Three Rivers Provider Network, Tika Diagnostics, Tocagen, Todos Medical, Tokra Medikal, Toronto Innovation Acceleration Partners, Total Testing Solutions, TPMENA, Transgenomic, Trivector Biomed, True Diagnostics, True North Laboratory, TTP Group, Tucker Medical, Tulane University, Tute Genomics, Two Pore Guys, U.K. Department for International Development, Ubiquitome, UCB, UK Government, Ultramedix Australasia, Unilab, Unilabs, United Nations Children Fund, United States Agency for International Development, University College Dublin, University College London, University of Bradford, University of Bristol, University of California Berkeley, University of Cambridge, University of Florida, University of Hong Kong, University of Manchester, University of Michigan, University of Minnesota, University of Ottawa, University of Oxford, University of Sunderland, University of Texas Health SCience Center at San Antonio, University of Washington, UPS Supply Chain Services, UrSure, US Army, US Department of Agriculture, US Government, US Navy, Valeant Pharmaceuticals, Vantage Health, Vela Diagnostics, Velox Biosystems, Ventana Medical Systems, Veravas, Verax Biomedical, Verily, Verinata Health, Vida Diagnostics, Vigilant Biosciences, Viral Hemorrhagic Fever Consortium, VisionQuest Biomedical, Visualant, Vital Connect, ViveBio, Vivera Pharmaceuticals, Vivione Biosciences, VolitionRX, Volk Optical, VWR International, Vyaire Medical, Vyripharm, Walter Reed Army Institute of Research, Waters Corporation, WaveForm Technologies, Wellbridge Health, Wellcome Trust, Windsor Pharmaceuticals, WinterLight Labs, Woom, Wuhan Kindstar Diagnostics, WuXi Biologics, XaTek, XCellCure, Yashraj Biotechnology, YBUX, YuYu Pharma, Zoetis, zPREDICTA, Zymo Research

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!